食品伙伴網(wǎng)訊 據(jù)美國FDA消息,9月8日美國FDA發(fā)布了嬰兒配方奶粉標(biāo)簽聲稱有關(guān)學(xué)術(shù)依據(jù)的指導(dǎo)草案,相關(guān)學(xué)術(shù)依據(jù)用于證明標(biāo)簽所列奶粉構(gòu)成/功能相關(guān)的聲稱。
嬰兒奶粉標(biāo)簽與標(biāo)識(shí)“結(jié)構(gòu)/功能”聲稱是指產(chǎn)品的效果或者組分對(duì)正常結(jié)構(gòu)或者身體功能的效果。例如奶粉標(biāo)簽上面的“助消化”。
該草案可幫助嬰兒配方奶粉制造商使產(chǎn)品標(biāo)簽結(jié)構(gòu)/功能聲稱符合真實(shí)性要求,而不是誤導(dǎo)消費(fèi)者。征求意見截止2016年11月8日。
部分原文報(bào)道如下:
The U.S. Food and Drug Administration has issued draft guidance for industry to help infant formula manufacturers making structure/function claims comply with the requirement that all claims in infant formula labels and labeling be truthful and not misleading.
“Structure/function” claims are statements made about the effects of a product or its constituent on the normal structure or function of the body. An example of a structure/function claim in infant formula labeling is a statement that the formula “supports digestion.”
原文鏈接:http://www.fda.gov/Food/NewsEvents/ConstituentUpdates/ucm514389.htm